摘要
目的观察伊布利特联合胺碘酮转复心房扑动(房扑)/心房颤动(房颤)的有效性及安全性。方法选择符合条件的患者88例,按制定的入选标准与排除标准将88例患者根据是否服用胺碘酮分为对照组和试验组。对照组:单用伊布利特;试验组:口服胺碘酮后联合伊布利特。口服胺碘酮组负荷量7~15g(3~4周内达到靶剂量)。伊布利特首剂1.0mg,10min内缓慢静脉注射,如给药10min后仍未转复为窦性心律,行第2次注射,剂量仍为1.0mg,观察开始给药后4h内转复的成功率、转复过程中用药剂量、用药前后的QT间期的差异及4h内不良反应的发生情况。结果①试验组房扑转复成功率(92%)高于对照组(56%),但差异无统计学意义(P=0.116);而房颤转复成功率试验组(76%)与对照组(44%)差异有统计学意义(P=0.010);试验组(80%)与对照组(47%)房扑和房颤总的转复成功率差异亦有统计学意义(P=0.003)。②在转复房扑、房颤成功的患者伊布利特使用剂量房扑[(1.1±0.4)mg]低于房颤[(1.7±0.4)mg],差异有统计学意义(P〈0.01)。③试验组与对照组使用伊布利特前QT间期(0.49±0.08)、(0.43±0.04)差异无统计学意义(P=0.760);2组使用伊布利特后QT间期(0.52±0.06)、(0.45±0.03),差异亦无统计学意义(P=0.150);试验组与对照组各自在注药前后QT间期均延长,差异有统计学意义(对照组P=-0.013;试验组P〈0.01)。④试验组有2例室性心动过速(发生率为2%)。1例在推药过程中发生尖端扭转型室性心动过速(Trip),经电复律终止,转为窦性心律、频发室性早搏,再次房颤继之再发Tdp,静脉注射2.5g硫酸镁终止;1例在转复成功5min后发生非持续单形性室性心动过速,自行终止。2组各发生2例窦性停搏,均在2-3s后自行或经胸外按压后恢复窦性心律。结论口服胺碘酮联合伊布利特转复房扑,房颤成功率高于单一用药,并可预防其复发,联合应用未增加不良事件的发生率。
Objective To evaluate the efficacy and safety of ibutilide and amiodarone on cardioversion in pa- tients with atrial flutter or atrial fibrillation (AFL/AF). Methods Eighty-eight patients who met eligibility were ran- domized to receive ibutilide alone (control group) or in combination with amiodarone (experimental group). Amiodarone was administered orally at an initial dose of 7-15 g, which was subject to up-titration to the targeted dose within 3 to 4 weeks. Ibutilide was administered intravenously, in a slow fashion (within 10 rain), at an initial dose of 1.0 mg, and if cardioversion failed, a repeated injection may be warranted. This entailed the determination of the rate of successful cardioversion at 4 hours, the dose needed during cardioversion, the difference in the QT interval before and after in- jection and the incidence of adverse events within 4 hours. Results Experimental group yielded a numerically but not statistically higher success cardioversion rate of AFL than control group (92% vs 56%, P=0.116). However, the success cardioversion rates of AF and AFL plus AF were statistically different (76% vs 44%, P=0.010; 80% vs 47%, P=0.003). Pateints with AFL were administered with a markedly lower dose of ibutilide for successful cardioversion than those with AF [(1.1±0.4) mg vs (1.7±0.4) mg, P〈0.01)]. There were no notable differences in the QTc prior to (0.49±0.08 vs 0.43±0.04,P=0.760) and after ibutilide injection (0.52±0.06 vs. 0.45±0.03, P=0.150) between the two groups. The extension of QTc before and after ibutilide injection was statistically different (P=0.013 for control group and P〈0.01 for experimental group). Of the two cases (2%) that developed ventricular tachycardia, one in experimental group elicited torsades de pointes during injection, which was converted to sinus rhythm and recurrent ventricular premature beats following 2.5 g MgSO4 intravenous injection, which again converted a secondary recurrent AF and subsequent torsades de pointes to sinus rhythm. The other case developed non-continuous monomorphous ventricular tachycardia that resolved per se at 5 minutes after successful conversion. Two patients in individual group elicited si- nus arrest which could be restored to sinus rhythm per se or by chest wall compressing after 2 to 3 seconds. Conslusion The successful conversion rate conferred by the addition of amiodarone is higher than that by either medica- tion alone. The combination of ibutilide and amiodarone may be worthwhile for prevention of recurrence of AF/AFL with a non-inferiority in the safety profiles.
出处
《中国药物与临床》
CAS
2014年第3期287-289,共3页
Chinese Remedies & Clinics
基金
山西省科技攻关项目(201103130182)
关键词
心房颤动
心房扑动
伊布利特
胺碘酮
Atrial fibrillation
Atrial flutter
Ibutilide
Amiodarone